Literature DB >> 10386556

Novel hMLH1 and hMSH2 germline mutations in African Americans with colorectal cancer.

T K Weber1, H M Chin, M Rodriguez-Bigas, B Keitz, R Gilligan, L O'Malley, E Urf, N Diba, J Pazik, N J Petrelli.   

Abstract

CONTEXT: Germline mutations of the DNA mismatch repair (MMR) genes hMLH1 and hMSH2 have been shown to cosegregate with the colorectal cancer phenotype in multiple hereditary nonpolyposis colorectal cancer (HNPCC) pedigrees. However, the frequency of these mutations among African American patients with colorectal cancer is unknown.
OBJECTIVE: To investigate the frequency of germline alterations of the DNA MMR genes hMLH1 and hMSH2 among African Americans affected by HNPCC and early-age onset colorectal cancer. DESIGN, SETTING, AND PATIENTS: Forty unrelated African American HNPCC and early-age onset colorectal cancer patients (8 women, 3 men) were identified from the cancer registry at a National Cancer Institute-designated referral center, 11 of whom were available for and agreed to study participation from January 1997 to February 1998. The mean age of the subjects was 44 years. An additional 50 age- and sex-matched African Americans without personal or family history of colorectal, endometrial, ovarian, urinary tract, or upper gastrointestinal tract malignancy were also studied as a polymorphism control population. In all subjects, genomic DNA was amplified by polymerase chain reaction for all hMLH1 and hMSH2 exons and screened using single-strand conformation polymorphism (SSCP) analysis. Samples demonstrating significant SSCP shifts underwent automated nucleotide sequencing analysis. MAIN OUTCOME MEASURE: Frequency of hMLH1 and hMSH2 germline alterations in the affected and control subjects.
RESULTS: Germline hMLH1 and hMSH2 mutations were detected in 3 (27%) of the African American colorectal cancer probands studied. Each mutation was novel. Two hMLH1 (an A-->T transversion at codon 26 and a GG-->AT substitution across codons 177 and 178) mutations and 1 hMSH2 mutation (a C-->T transition at codon 389) were identified in 3 female study subjects. Six other hMLH1 and hMSH2 alterations were detected but were presumed to be polymorphisms. Neither missense mutation (at codons 26 and 389) was detected in the control population.
CONCLUSIONS: The results of our analysis support an association between the 3 mutations reported and predisposition to colorectal cancer. Further studies are needed to define DNA MMR gene-associated colorectal cancer in African Americans, an understudied population at increased risk of fatal colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10386556     DOI: 10.1001/jama.281.24.2316

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  20 in total

Review 1.  Colorectal Cancer Disparity in African Americans: Risk Factors and Carcinogenic Mechanisms.

Authors:  Gaius J Augustus; Nathan A Ellis
Journal:  Am J Pathol       Date:  2017-11-09       Impact factor: 4.307

2.  Lynch syndrome in Tunisia: first description of clinical features and germline mutations.

Authors:  Sana Aissi-Ben Moussa; Amel Moussa; Nadia Kourda; Amel Mezlini; Nabil Abdelli; Farid Zerimech; Taoufik Najjar; Sarah Ben Jilani; Nicole Porchet; Farhat Ben Ayed; Mohamed Manai; Marie-Pierre Buisine
Journal:  Int J Colorectal Dis       Date:  2011-02-11       Impact factor: 2.571

Review 3.  TTD consensus document on the diagnosis and management of hereditary colorectal cancer.

Authors:  Pedro Pérez Segura; Carmen Guillén Ponce; Carmen Guillén Alonso; Teresa Ramón y Cajal; Raquel Serrano Blanch; Enrique Aranda
Journal:  Clin Transl Oncol       Date:  2010-05       Impact factor: 3.405

4.  Risk of colorectal cancer among Caucasian and African American veterans with ulcerative colitis.

Authors:  Jason K Hou; Jennifer R Kramer; Peter Richardson; Minghua Mei; Hashem B El-Serag
Journal:  Inflamm Bowel Dis       Date:  2011-08-29       Impact factor: 5.325

5.  Clinicopathological features and microsatellite instability (MSI) in colorectal cancers from African Americans.

Authors:  Hassan Ashktorab; Duane T Smoot; Haleh Farzanmehr; Marie Fidelia-Lambert; Bahram Momen; Linda Hylind; Christine Iacosozio-Dononue; John M Carethers; Ajay Goel; C Richard Boland; Francis M Giardiello
Journal:  Int J Cancer       Date:  2005-10-10       Impact factor: 7.396

6.  Prevalence of colon polyps detected by colonoscopy screening in asymptomatic black and white patients.

Authors:  David A Lieberman; Jennifer L Holub; Matthew D Moravec; Glenn M Eisen; Dawn Peters; Cynthia D Morris
Journal:  JAMA       Date:  2008-09-24       Impact factor: 56.272

7.  Genotyping possible polymorphic variants of human mismatch repair genes in healthy Korean individuals and sporadic colorectal cancer patients.

Authors:  Jin C Kim; Seon A Roh; Kum H Koo; In H Ka; Hee C Kim; Chang S Yu; Kang H Lee; Jung S Kim; Han I Lee; Walter F Bodmer
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

8.  Prevalence of advanced colorectal neoplasia in white and black patients undergoing screening colonoscopy in a safety-net hospital.

Authors:  Paul C Schroy; Alison Coe; Clara A Chen; Michael J O'Brien; Timothy C Heeren
Journal:  Ann Intern Med       Date:  2013-07-02       Impact factor: 25.391

9.  Mutation spectrum and risk of colorectal cancer in African American families with Lynch syndrome.

Authors:  Rodrigo Santa Cruz Guindalini; Aung Ko Win; Cassandra Gulden; Noralane M Lindor; Polly A Newcomb; Robert W Haile; Victoria Raymond; Elena Stoffel; Michael Hall; Xavier Llor; Chinedu I Ukaegbu; Ilana Solomon; Jeffrey Weitzel; Matthew Kalady; Amie Blanco; Jonathan Terdiman; Gladis A Shuttlesworth; Patrick M Lynch; Heather Hampel; Henry T Lynch; Mark A Jenkins; Olufunmilayo I Olopade; Sonia S Kupfer
Journal:  Gastroenterology       Date:  2015-08-03       Impact factor: 22.682

10.  Whites and blacks have similar risk of metachronous advanced colorectal neoplasia.

Authors:  Joann Kwah; Paul C Schroy; Brian C Jacobson; Audrey H Calderwood
Journal:  Dig Dis Sci       Date:  2014-04-04       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.